Please ensure Javascript is enabled for purposes of website accessibility

‘Veterinary Dermatology’ Publishes ElleVet Sciences Atopic Dermatitis Study

Glenn Polyn//June 2, 2022//

‘Veterinary Dermatology’ Publishes ElleVet Sciences Atopic Dermatitis Study

Glenn Polyn //June 2, 2022//

Listen to this article

Press release: ElleVet Sciences

A groundbreaking study, investigating the results of ElleVet Sciences CBD+CBDA oil and its efficacy on dogs with atopic dermatitis, was completed, and results show a resounding success. Analysis of the data show that over 65 percent of the dogs enrolled in the study had a significant improvement in skin itchiness. The paper is published in “Veterinary Dermatology,” a prestigious veterinary publication.

While CBD has been widely believed to have potential as a treatment option for atopic dermatitis, there have been minimal research studies prior to this study.

Led by Dr. Andrew Rosenberg of the Dermatology Center of New York and New Jersey, the research team conducted a year-long study examining a month-long treatment in a placebo blinded controlled clinical trial where dogs were either given a placebo or ElleVet Sciences’ CBD+CBDA oil. When compared, the itchiness scores recorded by owners dropped significantly for dogs on the ElleVet Sciences’ oil compared to dogs on the placebo. All dogs enrolled did not respond to the sesame oil base as a control group, showing that ElleVet Sciences has a significant positive impact on itchiness in dogs, which is one of the most common complaints from dog owners. No significant side effects were noted by owners, and when asked if they would continue this treatment, all the respondents are planning to continue usage.

“This is a really positive response since these dogs were all refractory to commonly used products,” said Dr. Joe Wakshlag, chief medical officer of ElleVet Sciences. “This can be a regimen that is safe and effective and is a worthwhile addition to the current regimen and could be considered a first line of defense and can be used in conjunction with other products when necessary. This study was a huge success and we at ElleVet are extremely excited to share the results with the veterinary community.”

According to ElleVet Sciences co-founder Amanda Howland, “We are very pleased with the results of this study. Dermatological issues are one of the most common complaints from pet owners, and something that is a huge source of stress for both pets and pet owners. The results are even better than we anticipated, and we are thrilled to be able to share these results and help dogs with this issue.”

“The dosing in the study was specific for atopic dermatitis, highlighting the need for accurate dosing in CBD+CBDA products. Sixty five percent of dogs had a clinically significant reduction in itching, which makes this study a resounding success,” addedDr. Wakshlag.

ElleVet Sciences is a leading science-focused pet CBD+CBDA company based in Portland, Maine, and the first and only company to conduct clinical trials with proven results using their cannabinoid and terpene oil blend. ElleVet was founded by Howland and Christian Kjaer in 2017, and the entire ElleVet team combines science, veterinary backgrounds with a dedication to animals through research and innovation.